Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Sanofi Ord Shs SNYNF

Healthcare

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Add To Watchlist

Recent & Breaking News (OTCPK:SNYNF)

Where Does Zika Virus Vaccine Research Stand Now?

Benzinga.com August 12, 2017

This Week's Pharma, Energy IPOs

Benzinga.com August 7, 2017

Investor Network: Sanofi to Host Earnings Call

Accesswire July 31, 2017

Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER

PR Newswire July 31, 2017

Sanofi Receives CHMP Positive Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis

PR Newswire Europe Non Regulatory July 21, 2017

Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis

PR Newswire July 21, 2017

Sanofi Pasteur Ships First of its U.S. Influenza Vaccine Doses for 2017-2018 Season

PR Newswire July 17, 2017

Alnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors

Business Wire July 10, 2017

Breakfast Technical Briefing on Drug Makers Stocks -- Bristol Myers Squibb, Eli Lilly, AstraZeneca, and Sanofi

PR Newswire July 5, 2017

American Academy of Family Physicians Foundation Launches Highlight on VACCINATIONS 4 TEENS to Help Address Teen Under-Vaccination

PR Newswire June 27, 2017

Sanofi Announces Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union

PR Newswire Europe Non Regulatory June 27, 2017

Sanofi Announces Licensing of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union

PR Newswire Europe Non Regulatory June 27, 2017

Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union

PR Newswire June 27, 2017

Dan Loeb's Activist Campaign Against Nestle Goes Against Decades Of History

Benzinga.com June 26, 2017

Sanofi Launches "Action 2017", a Worldwide Employee Stock Purchase Plan

GlobeNewswire June 15, 2017

Start Your Morning With a Cup of Coffee and an Ounce of Dengue Prevention

PR Newswire Asia June 14, 2017

Wall Street's M&A Chatter From June 13: Brookdale, Etsy, Roche-Tesaro

Benzinga.com June 14, 2017

Wall Street's M&A Chatter From June 12: Neuroderm, Penn Virginia, Tesaro, Synaptics-Conexant

Benzinga.com June 13, 2017

Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia

PR Newswire June 11, 2017

Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia

PR Newswire June 11, 2017